Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
SMURF2 inhibits autophagic control of Mycobacterium tuberculosis in macrophages
Priscila C. Campos, Kathryn C. Rahlwes, Victoria A. Ektnitphong, Beatriz R.S. Dias, Kubra F. Naqvi, Samuel Alvarez-Arguedas, Michael U. Shiloh
Priscila C. Campos, Kathryn C. Rahlwes, Victoria A. Ektnitphong, Beatriz R.S. Dias, Kubra F. Naqvi, Samuel Alvarez-Arguedas, Michael U. Shiloh
View: Text | PDF
Research Article Immunology Infectious disease Microbiology

SMURF2 inhibits autophagic control of Mycobacterium tuberculosis in macrophages

  • Text
  • PDF
Abstract

Autophagy is a critical host defense mechanism that restricts intracellular pathogens such as Mycobacterium tuberculosis. A key step in this process is the ubiquitination of M. tuberculosis or M. tuberculosis–associated structures. The E3 ligase Smad-specific E3 ubiquitin protein ligase 1 (SMURF1) catalyzes K48-linked ubiquitination, promoting bacterial clearance. However, the function of its homolog, SMURF2, in host defense remains undefined. Here, we demonstrate that Smurf2 deletion in murine macrophages increases SMURF1 levels, enhances LC3B lipidation, augments K48 ubiquitination of M. tuberculosis–associated structures, and reduces intracellular M. tuberculosis replication. These effects are reversed by Smurf1 deletion, supporting a role for SMURF1 in SMURF2-dependent control of M. tuberculosis. Mice with myeloid-specific Smurf2 deletion exhibit modestly prolonged survival after aerosol M. tuberculosis infection. In human macrophages, SMURF2 knockdown or its pharmacological inhibition with the HECT E3-ligase inhibitor Heclin reduces M. tuberculosis replication. Together, our findings identify SMURF2 as a negative regulator of macrophage control of M. tuberculosis and support further investigation of SMURF2 as a potential target for host-directed therapy in tuberculosis.

Authors

Priscila C. Campos, Kathryn C. Rahlwes, Victoria A. Ektnitphong, Beatriz R.S. Dias, Kubra F. Naqvi, Samuel Alvarez-Arguedas, Michael U. Shiloh

×

Figure 3

Smurf2 KO affects M. tuberculosis replication through SMURF1 in murine macrophages.

Options: View larger image (or click on image) Download as PowerPoint

Smurf2 KO affects M. tuberculosis replication through SMURF1 in murine ...
(A) Immunoblot analysis to detect SMURF2 and SMURF1 in BV2-WT, Smurf2-KO, Smurf1-KO, and Smurf2/1-KO cells under basal conditions. (B) CFU of M. tuberculosis in BV2-WT, Smurf2-KO, Smurf1-KO, and Smurf2/1-KO BV2 cells at different time points (mean ± SD of a representative experiment out of 3 independent experiments, each performed in quadruplicate, ns, nonsignificant, *P ≤ 0.05 and ***P ≤ 0.001; 2-way ANOVA, with multiple comparisons). (C) Immunoblot analysis of LC3B-II levels in BV2-WT, Smurf2-KO, Smurf1-KO, and Smurf2/1-KO cells, infected or not with M. tuberculosis (MOI 5) at 24 hours after infection. (D) Densitometric quantification of LC3B-II levels, as shown in C (mean ± SD of 3 independent experiments, ns, nonsignificant, **P ≤ 0.01; 2-way ANOVA, with multiple comparisons).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts